Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (1-10 of 395) with videos related to

Pageof 40
Sort By:
Oncology (Williston Park, N.Y.)|October 12, 2002
Targeted therapy in non-small-cell lung cancerRoy S Herbst
Expert Opinion on Investigational Drugs|May 31, 2002
ZD1839: targeting the epidermal growth factor receptor in cancer therapyRoy S Herbst
Seminars in Oncology|July 4, 2003
Erlotinib (Tarceva): an update on the clinical trial programRoy S Herbst
American Journal of Medical Genetics|January 1, 1980
Nonspecific X-linked mental retardation I: a review with information from 24 new familiesD S Herbst
Clinical Lung Cancer|January 24, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancerRoy S Herbst
International Journal of Radiation Oncology, Biology, Physics|May 15, 2004
Review of epidermal growth factor receptor biologyRoy S Herbst
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
EGFR inhibition in NSCLC: the emerging role of cetuximabRoy S Herbst
Expert Opinion on Emerging Drugs|October 27, 2006
Therapeutic options to target angiogenesis in human malignanciesRoy S Herbst
Clinical Lung Cancer|January 15, 2004
Targeted therapy using novel agents in the treatment of non-small-cell lung cancerRoy S Herbst
British Journal of Cancer|June 2, 2005
Role of novel targeted therapies in the clinicR S Herbst
Pageof 40

Showing results (1-10 of 395) with videos related to

Sort By:
Pageof 40
Oncology (Williston Park, N.Y.)|October 12, 2002
Targeted therapy in non-small-cell lung cancerRoy S Herbst
Expert Opinion on Investigational Drugs|May 31, 2002
ZD1839: targeting the epidermal growth factor receptor in cancer therapyRoy S Herbst
Seminars in Oncology|July 4, 2003
Erlotinib (Tarceva): an update on the clinical trial programRoy S Herbst
American Journal of Medical Genetics|January 1, 1980
Nonspecific X-linked mental retardation I: a review with information from 24 new familiesD S Herbst
Clinical Lung Cancer|January 24, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancerRoy S Herbst
International Journal of Radiation Oncology, Biology, Physics|May 15, 2004
Review of epidermal growth factor receptor biologyRoy S Herbst
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
EGFR inhibition in NSCLC: the emerging role of cetuximabRoy S Herbst
Expert Opinion on Emerging Drugs|October 27, 2006
Therapeutic options to target angiogenesis in human malignanciesRoy S Herbst
Clinical Lung Cancer|January 15, 2004
Targeted therapy using novel agents in the treatment of non-small-cell lung cancerRoy S Herbst
British Journal of Cancer|June 2, 2005
Role of novel targeted therapies in the clinicR S Herbst
Pageof 40